Novo Nordisk Investor Presentation - First Nine Months of 2016
Investor presentation
First nine months of 2016
Slide 13
Updated R&D strategy including a raised innovation
threshold for R&D projects specifically within diabetes
Utilisation of core protein capabilities to
enter adjacent areas
Stem cells in T1D
Nephropathy
T1D intervention
Pre-diabetes
Haemophilia: Novel
by-passing agents
NASH
Core areas
CV disease
Blood glucose regulation incl
insulin resistance
Obesity treatment
Haemophilia: Coagulation factor
therapy
Growth hormone treatment
T1D: Type 1 diabetes; NASH: Non-alcoholic steatohepatitis; CV: Cardiovascular
changing
diabetes®
Updated R&D strategy
R&D strategy and priorities have been updated to reflect the
increasingly challenging payer environment, particularly in
the US market, by applying an even higher innovation
threshold for starting and progressing R&D projects within
diabetes
• Intensified focus on exploring current projects into adjacent
disease areas of high unmet need including NASH, CVD and
CKD
•
•
Build research portfolios via strengthened activities related to
in-licensing of early stage projects and enhanced external
academic collaborations
Discontinuation of oral insulin and combinations involving
oral insulin, as well as a number of changes to the portfolio
of early-stage projects will also be implemented, reflecting
the required higher innovation threshold
NASH: Non-alcoholic steatohepatitis; CVD: Cardiovascular disease;
CKD: Chronic kidney disease
novo nordiskView entire presentation